Publication number: 20250345431
Abstract: Provided herein are genetically engineered T cells containing a chimeric antigen receptor (CARs), and related methods and uses thereof in allogeneic cell therapy. In some embodiments, the T cells are genetically engineered with a CAR and are further genetically engineered by one or more strategies to reduce host immune recognition of the engineered T cells, such as by heterologous expression of one or more additional transgenes and by genetic disruption to reduce or eliminate expression or one or more endogenous protein. Also provided are cell compositions containing the engineered T cells, and related methods, kits and systems for producing the engineered T cells. Also provided are methods of making and using the engineered T cells for cell therapy, including in connection with cancer immunotherapy comprising adoptive transfer of the engineered T cells.
Type:
Application
Filed:
May 9, 2025
Publication date:
November 13, 2025
Applicant:
Juno Therapeutics, Inc.
Inventors:
CALVIN CHAN, CEDRIC CLEYRAT, LUCREZIA COLONNA, CYR CLOVIS CHUA DE IMUS, GABRIELA DIAZ, JENNA FERNANDEZ, NATALYA ALEKSANDRA GOLOVIZNINA, GABRIELA HERNANDEZ-HOYOS, CHRISTOPHER MARK HILL, XUEZHOU HOU, AKSHATA IJANTKAR, DARREN M. KAMIKURA, WEI-MING KAO, ASHLEY KERN KOEGEL, ALEXIS LITKE, RUTH AMANDA SALMON, JIANBIN WANG, PAUL RICHARD WEINGARDEN, JOHN-MICHAEL WILLIFORD, SARAH KATHERINE WILSON, PEI YANG